Education
About Us
Working with TipRanks
Follow Us
OncoCyte Corp (OCX)
NASDAQ:OCX
Earnings Data
Report Date
May 20, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.24Last Year’s EPS
-0.62Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 24, 2025
|% Change Since: -8.11%
|Next Earnings Date:May 20, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements, including the launch of GraftAssure, strategic partnerships, clinical advancements, and financial success. However, there are concerns about potential regulatory delays due to external factors. Despite these challenges, the overall outlook remains positive with expectations of growth and expansion.Company Guidance
In the recent call, Oncocyte provided a comprehensive update on their progress and future plans, focusing on several key metrics. They highlighted the successful launch of GraftAssure, a kidney transplant test, and its role in improving assay design and user experience. They discussed the upcoming regulatory submissions in the US and Europe, with a projected timeline for FDA approval by mid-2026. The potential expansion of their total addressable market (TAM) by up to 20% was emphasized, supported by a breakthrough designation from the FDA for their assay's role in a study published in the New England Journal of Medicine. Financially, Q4 saw $1.5 million in pharma services revenue with a 40% gross margin, surpassing expectations. Oncocyte also reported cash flow management efforts, with Q4 outgoing cash flow at $5.6 million, and an end-of-year cash balance of $10 million, bolstered by a recent $29 million fundraise. The call concluded with a commitment to sign 20 transplant centers by the end of 2025, aiming for $20 million in future annual recurring revenue.Launch of GraftAssure and Market Expansion
Successfully launched GraftAssure, a research use-only kidney transplant test, with leading transplant centers. The test has expanded the total addressable market by up to 20% and is expected to contribute to meaningful market growth over the next five years.
Strategic Partnership with Bio-Rad Laboratories
Secured a key strategic partner in Bio-Rad Laboratories, which has participated in all three equity funding rounds over the last year. Bio-Rad's support is expected to mitigate expenses and assist in clinical trial and commercialization efforts.
Medicare Claims Expansion and Regulatory Progress
Achieved Medicare claims expansion to monitor high-risk transplant patients and had a positive pre-submission meeting with the FDA, preparing for final submission later this year.
Financial Performance and Fundraising Success
Reported Q4 pharma services revenue of $1.5 million with a gross margin of 40%. Ended the year with $10 million in cash and raised an additional $29 million in February through a clean transaction with no incentive warrants or discounts.
Clinical and Scientific Advancements
Published a groundbreaking study in the New England Journal of Medicine, leading to FDA breakthrough designation for felzartamab. Demonstrated assay's ability to detect organ rejection 11 months ahead of standard protocols.
Strong Team and Operational Efficiency
Strengthened leadership team with new CFO Andrea James and Consulting Chief Medical Officer Dr. Paul Billings. Continued focus on operational efficiency, with outgoing cash flow favorable to targeted spend.
---
OCX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
OCX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 24, 2025 | $3.33 | $3.04 | -8.71% |
| Nov 12, 2024 | $3.00 | $2.94 | -2.00% |
| Aug 08, 2024 | $3.08 | $3.12 | +1.30% |
| May 15, 2024 | $2.95 | $3.07 | +4.07% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does OncoCyte Corp (OCX) report earnings?
OncoCyte Corp (OCX) is schdueled to report earning on May 20, 2025, TBA Not Confirmed.
What is OncoCyte Corp (OCX) earnings time?
OncoCyte Corp (OCX) earnings time is at May 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is OCX EPS forecast?
OCX EPS forecast for the fiscal quarter 2025 (Q1) is -0.24.
---